Measuring infliximab and adalimumab blood levels in IBD patients, prospective observations from a single center compared to a time period before regular use of these measurements.

Conditions: Inflammatory bowel diseases, IBD, inflammatoire darm ziekten, Crohn's disease, Ziekte van Crohn, ulcerative colitis, colitis ulcerosa, IBD-U, IBD-unclassified, biologicals, TNFalpha blockers, anti-TNF-alfa, infliximab, IFX, adalimumab, ADM, therapeutic drug monitoring, TDM, trough levels, medicatiespiegels, dalspiegels.

Registration Number: NL-OMON29021

Lead Sponsor: oordwest Ziekenhuisgroep

Brief Summary: Intentions are publication in an international peer reviewed scientific magazine.

Detailed Description: Not available

Recruitment & Eligibility

Status: Other

Sex: Not specified

Target Recruitment: 275

Inclusion Criteria

For the historical cohort:

- All patients who were 18 years and older on 01-01-2016 and no longer being cared for by our paediatricians

Exclusion Criteria

-Any IBD-patient (who was) participating in a clinical trial for one of these biologicals that dictated/s an alternative treatment regimen than was/is used in clinical practice.

- Any IBD patient whose treatment indication for infliximab or adalimumab is/was not primarily for IBD during the study periods (such as rheumatoid arthritis or psoriasis).

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To explore the proportion of patients needing rescue therapy in the form of steroids, surgery and/or discontinuation or switch of the TNF-alpha blocker due to refractory disease in a one year period

Secondary Outcome Measures